BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

European equity markets may thrive with monetary easing, fiscal expansion, and controlled inflation, despite risks from ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” first quarter ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Analysts forecast explosive growth ahead for AI in healthcare, with MarketsandMarkets projecting the market to surge past $110 billion by 2030 on a 38.6% compound annual growth rate. Accenture goes ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...